JNJ Reports Strong Q3 2025 Profit and Raises Sales Outlook

Johnson & Johnson (JNJ.US) reported robust financial results for the third quarter ended September 28, 2025, with adjusted diluted earnings per share (EPS) of $2.80, surpassing the analyst estimate of $2.77. This represents a substantial 15.7% increase compared to the prior year. The company also posted reported sales of $23.993 billion, growing 6.8% year-over-year, although it fell short of the analyst revenue estimate of $23.755 billion.

Strong Segment Performance

The Innovative Medicine segment demonstrated strong growth, with worldwide operational sales increasing by 5.3%. This was primarily driven by key products such as DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience.

The MedTech segment also contributed significantly, reporting a 5.6% increase in worldwide operational sales. This performance was fueled by electrophysiology products, Abiomed and Shockwave in Cardiovascular, wound closure products in General Surgery, and Surgical Vision.

Strategic Orthopaedics Business Separation

Johnson & Johnson announced its intent to separate its Orthopaedics business, which will operate as DePuy Synthes. This strategic move aims to enhance the focus of Johnson & Johnson on higher-growth and higher-margin markets within its Innovative Medicine and MedTech segments, specifically Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision.

The standalone DePuy Synthes is expected to be the largest, most comprehensive orthopaedics-focused company, addressing a market opportunity exceeding $50 billion and serving approximately seven million patients annually. Management anticipates this separation will improve top-line growth and operating margins for Johnson & Johnson.

Raised Full-Year Sales Outlook

Building on its strong third-quarter performance, Johnson & Johnson has increased its full-year estimated reported sales guidance for 2025. The company now expects reported sales to be between $93.5 billion and $93.9 billion, with a midpoint of $93.7 billion, representing a 5.7% increase at the midpoint. This revised outlook reflects continued confidence in the company's growth trajectory.

The company also reaffirmed its full-year adjusted EPS guidance of $10.80 to $10.90, with a midpoint of $10.85, absorbing higher tax costs. This guidance reflects an expected year-over-year increase of 8.7% at the midpoint for adjusted EPS.